Consistent with this idea, blockade of prolactin by bromocriptine, a dopamine D2–receptor agonist, prevented the onset of disease in an experimental model of peripartum cardiomyopathy and appeared successful in small pilot trials. The gene discussed is PRL; the disease is peripartum cardiomyopathy.